Reports of "satisfactory relief" by IBS patients receiving usual medical care are confounded by baseline symptom severity and do not accurately reflect symptom improvement

American Journal of Gastroenterology

Volumn 101, Issue 5, 2006, Pages 1057-1065

  Whitehead, William E ^a   Palsson, Olafur S ^a   Levy, Rona L ^b   Feld, Andrew D ^c   VonKorff, Michael ^c   Turner, Marsha ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c CENTER FOR HEALTH STUDIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CLINICAL RESEARCH; CORRELATION ANALYSIS; DISEASE SEVERITY; EMOTIONAL STRESS; ENTERITIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL CARE; OUTCOMES RESEARCH; PATIENT SATISFACTION; PRIORITY JOURNAL; QUALITY OF LIFE; SENSITIVITY ANALYSIS; STANDARD; SYMPTOMATOLOGY; VALIDATION PROCESS;

CLINICAL TRIALS; CONFOUNDING FACTORS (EPIDEMIOLOGY); FEMALE; HUMANS; IRRITABLE BOWEL SYNDROME; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PATIENT SATISFACTION; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; STRESS, PSYCHOLOGICAL;

EID: 33646547623     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2006.00535.x     Document Type: Article

References (33)

1. VanZanten SJOV Talley NJ Bytzer P et al Design of treatment trials for the functional gastrointestinal disorders In Drossman DA Corazziari E Talley NJ Thompson WG Whitehead WE eds. Rome II: The Functional Gastrointestinal Disorders 2nd Ed. McLean VA Degnon Associates 2000 577 622
2. Mangel AW Hahn BA Heath AT et al Adequate relief as an endpoint in clinical trials in irritable bowel syndrome J Int Med Res 1998 26 76 81
3. Kellow J Lee OY Chang FY et al An Asia-Pacific, double blind, placebo controlled, randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome Gut 2003 52 671 6
4. Camilleri M Mayer EA Drossman DA et al Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist Aliment Pharmacol Ther 1999 13 1149 59
5. Bardhan KD Bodemar G Geldof H et al A double-blind, randomized, placebo-controlled dose-ranging study to evaluate the efficacy of alosetron in the treatment of irritable bowel syndrome Aliment Pharmacol Ther 2000 14 23 34
6. Camilleri M Northcutt AR Kong S et al Efficacy and safety of alosetron in women with irritable bowel syndrome: A randomised, placebo-controlled trial Lancet 2000 355 1035 40
7. Camilleri M Chey WY Mayer EA et al A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome Arch Intern Med 2001 161 1733 40
8. Chey WD Chey WY Heath AT et al Long-term safety and efficacy of alosetron in women with severe diarrhea-predominant irritable bowel syndrome Am J Gastroenterol 2004 99 2195 203
9. Lembo T Wright RA Bagby B et al Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome Am J Gastroenterol 2001 96 2662 70
10. Watson ME Lacey L Kong S et al Alosetron improves quality of life in women with diarrhea-predominant irritable bowel syndrome Am J Gastroenterol 2001 96 455 9
11. Miner PB Pruitt RE Carter F et al Cilansetron is efficacious in treating diarrheal symptoms in irritable bowel syndrome with diarrhea predominance (IBS-D) over 3 months Gastroenterology 2005 128 suppl 2 A29
12. Francisconi CF Drossman DA Mayer EA et al Relief of symptoms in irritable bowel syndrome with diarrhea predominance (IBS-D) patients decreases after blinded withdrawal of Cilansetron treatment Gastroenterology 2005 128 suppl 2 A465
13. Nyhlin H Bang C Elsborg L et al A double-blind, placebo-controlled, randomized study to evaluate the efficacy, safety and tolerability of tegaserod in patients with irritable bowel syndrome Scand J Gastroenterol 2004 39 119 26
14. Muller-Lissner SA Fumagalli I Bardhan KD et al Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation Aliment Pharmacol Ther 2001 15 1655 66
15. Muller-Lissner S Koch G Talley NJ et al Subject's Global Assessment of Relief: An appropriate method to assess the impact of treatment on irritable bowel syndrome-related symptoms in clinical trials J Clin Epidemiol 2003 56 310 6
16. Francis CY Morris J Whorwell PJ The irritable bowel severity scoring system: A simple method of monitoring irritable bowel syndrome and its progress Aliment Pharmacol Ther 1997 11 395 402
17. Whitehead WE Levy RL Von KM et al The usual medical care for irritable bowel syndrome Aliment Pharmacol Ther 2004 20 1305 15
18. Thompson WG Longstreth G Drossman DA et al Functional bowel disorders and functional abdominal pain In Drossman DA Corazziari E Talley NJ Thompson WG Whitehead WE eds. Rome II: The Functional Gastrointestinal Disorders 2nd Ed. McLean VA Degnon Associates 2000 351 432
19. Patrick DL Drossman DA Frederick IO et al Quality of life in persons with irritable bowel syndrome - Development and validation of a new measure Dig Dis Sci 1998 43 400 11
20. Drossman DA Patrick DL Whitehead WE et al Further validation of the IBS-QOL: A disease-specific quality-of-life questionnaire Am J Gastroenterol 2000 95 999 1007
21. Whitehead WE Levy RL Von Korff MV et al Usual medical care for irritable bowel syndrome Aliment Pharmacol Ther 2004 20 1305 15
22. Saunders KW Stergachis A Von Korff M Group health cooperative of puget sound In Strom BL ed. Pharmacoepidemiology 2nd Ed. New York John Wiley 1994 247 62
23. Practice Management Information Corporation ICD9-CM: International Classification of Diseases, 9th Revision, Clinical Modification Los Angeles CA Practice Management Information Corporation 2003
24. Drossman DA Corazziari E Talley NJ et al Rome II. The Functional Gastrointestinal Disorders. Diagnosis, Pathophysiology and Treatment: A Multinational Consensus McLean VA Degnon Associates 2000
25. Derogatis LR BSI 18 Brief Symptom Inventory 18: Administration, scoring, and procedures manual Minneapolis MN NCS Pearson, Inc 2000
26. Bijkerk CJ de Wit NJ Muris JW et al Outcome measures in irritable bowel syndrome: Comparison of psychometric and methodological characteristics Am J Gastroenterol 2003 98 122 7
27. Drossman DA Leserman J Nachman G et al Sexual and physical abuse in women with functional or organic gastrointestinal disorders Ann Intern Med 1990 113 828 33
28. Drossman DA Talley NJ Leserman J et al Sexual and physical abuse and gastrointestinal illness. Review and recommendations Ann Intern Med 1995 123 782 94
29. Drossman DA Whitehead WE Toner BB et al What determines severity among patients with painful functional bowel disorders? Am J Gastroenterol 2000 95 974 80
30. Payne A Blanchard EB A controlled comparison of cognitive therapy and self-help support groups in the treatment of irritable bowel syndrome J Consult Clin Psychol 1995 63 779 86
31. Greene B Blanchard EB Cognitive therapy for irritable bowel syndrome J Consult Clin Psychol 1994 62 576 82
32. Meissner JS Blanchard EB Malamood HS Comparison of treatment outcome measures for irritable bowel syndrome Appl Psychophysiol Biofeedback 1997 22 55 62
33. Corazziari E Bytzer P Delvaux M et al Clinical trial guidelines for pharmacological treatment of irritable bowel syndrome Aliment Pharmacol Ther 2003 18 569 80